Aptamer Group Share News (APTA)

EARNINGS AND TRADING: Zenova's Kitemark award; Carnival's eyes savings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and Monday and not separately reported by Alliance News:

Aptamer inks new Optimer+ transplant rejection therapy partnership

(Alliance News) - Aptamer Group PLC on Thursday said it has partnered with Kairos Biotech Ltd for Optimer+ transplant rejection therapies.

Aptamer submits patent application for Optimer binders

(Alliance News) - Aptamer Group PLC on Monday said it filed a patent application aimed at supporting the next stages of commercial advancement with Unilever PLC.

Aptamer applies for patent over binder sequences developed with Unilever

(Sharecast News) - Aptamer Group announced the submission of a patent application safeguarding newly-crafted Optimer binder sequences on Monday.

EARNINGS AND TRADING: Arbuthnot ups payout as profit more than doubles

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Aptamer shares jump on successful Unilever contract progression

(Alliance News) - Aptamer Group PLC shares rose on Monday, after it noted progression on its contract with Unilever PLC.

Aptamer says new Optimer+ delivers improved results

(Alliance News) - Aptamer Group PLC on Tuesday said its new Optimer+ platform delivers improved results compared to standard binders.

Aptamer and Neuro-Bio begin Alzheimer's test development second phase

(Alliance News) - Aptamer Group PLC on Thursday said it has entered the second phase of developing Optimer binders for the early diagnosis of Alzheimer's disease alongside Neuro-Bio Ltd.

Aptamer shares plunge as half-year revenue to fall by 70%

(Alliance News) - Aptamer Group PLC on Monday said it will miss its half-year revenue expectations as a result of weak customer demand.

Aptamer reports decent technical, commercial progress

(Sharecast News) - Aptamer Group reported solid progress on both the technical and commercial fronts on Friday as it held its annual general meeting.

Aptamer inks £0.55m agreement with biotech firm

(Sharecast News) - Aptamer Group announced a significant agreement with a biotechnology company on Thursday, focussed on genetic medicines.

IN BRIEF: Aptamer inks deal for Optimer discovery with biotech firm

Aptamer Group PLC - York-based biotech firm - Signs material agreement with unnamed biotechnology company, focused on developing genetic medicines. Aptamer will use its platform to discover Optimer binders to enable specific targeting of genetic medicines to specific cell types. Says it will receive up to GBP553,000 in development fees for discovering and developing the Optimer binders. Work is expected to start shortly and is expected to be completed within the current financial year. Optimer binders are a novel class of molecules for selectively targeting new biomarkers and tissues. Chief Technical Officer Arron Tolley says: "This project builds on the work we have been doing in drug delivery since being refunded and supports the need for new delivery modalities within the genetic medicines space. Targeting oligonucleotide therapeutics beyond hepatocytes remains a challenge across the industry; we believe the properties of Optimers make them suitable for developing precision-guided therapies and that Optimer-targeted therapies may represent the next stage in targeted drug delivery."

UK shareholder meetings calendar - next 7 days

EARNINGS AND TRADING: Aptamer revenue falls, loss widens

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

LONDON MARKET CLOSE: Stocks fail to shine despite dovish sentiment

(Alliance News) - Stock prices in London closed mixed on Monday, whilst US markets opened higher, with investors continuing to digest hopes that interest rates have peaked.